DONSON-Related Microcephalic Primordial Dwarfism: Comprehensive Research Report

1. Disease Information

Overview. DONSON-related disorder is a rare, autosomal recessive (with rare de novo cases) microcephalic primordial dwarfism (MPD) caused by biallelic (or, uncommonly, de novo monoallelic) hypomorphic variants in DONSON (Downstream Neighbor Of SON), a gene encoding an essential replisome/replication-initiation factor. Because complete loss of DONSON is embryonic lethal, all disease-causing alleles identified to date are partial loss-of-function ("hypomorphic") — no patient carries a biallelic combination of two complete null (nonsense/frameshift) alleles (PMID:28191891). The disorder spans a clinical continuum rather than a single discrete syndrome, ranging from prenatally/perinatally lethal microcephaly-micromelia syndrome (MIMIS) at the severe end, through Meier-Gorlin syndrome (MGS)-like and Seckel-syndrome-like presentations, to the comparatively milder microcephaly, short stature, and limb abnormalities (MISSLA) phenotype, plus rare femoral-facial syndrome (FFS)-like presentations (PMID:31407851; PMC6528082).

Key identifiers: - Gene: DONSON, HGNC:2993, chromosome 21q22.11, UniProt Q9NYP3, protein "DNA replication fork stabilization factor DONSON" (566 aa, ~62.7 kDa, 10 coding exons; transcript NM_017613) - OMIM gene: 611428 (DOWNSTREAM NEIGHBOR OF SON; DONSON) - OMIM phenotypes: - #617604 — Microcephaly, Short Stature, and Limb Abnormalities (MISSLA) - #251230 — Microcephaly-Micromelia Syndrome (MIMIS) - Additional overlapping entries for Meier-Gorlin syndrome and Seckel-like presentations attributed to DONSON - Orphanet: ORPHA:572768 (Microcephaly-micromelia syndrome); ORPHA:572773 (Microcephaly-short stature-limb abnormalities syndrome); gene page "DONSON — DNA replication fork stabilization factor DONSON" (orpha.net) - MONDO: parent grouping term MONDO:0017950 (microcephalic primordial dwarfism); disease-specific MONDO terms map to the MISSLA/MIMIS/MGS-DONSON entries - GARD/NIH: "DONSON-related microcephaly-short stature-limb abnormalities spectrum" (rarediseases.info.nih.gov/diseases/22314) - Data is derived from aggregated case series and pedigrees* (exome/genome sequencing cohorts of families with microcephalic dwarfism), not large EHR-scale registries — the total published patient count across all DONSON-related phenotypes is on the order of 40–50 individuals as of the most recent literature.

Synonyms: DONSON deficiency; DONSON-related microcephalic primordial dwarfism; DONSON-related cell cycle-opathy; Meier-Gorlin syndrome 8 / DONSON-related MGS; Seckel-like syndrome (DONSON-related); Microcephaly-Micromelia Syndrome (MIMIS); Microcephaly, Short Stature and Limb Abnormalities (MISSLA); DONSON-related femoral-facial syndrome.

2. Etiology

Causal factor: Purely genetic/molecular — biallelic hypomorphic pathogenic variants in DONSON impairing (but not abolishing) its replisome function. A minority of reported cases are compound heterozygous with one de novo allele (PMC6936249).

Genetic risk factors: - Missense, splice-site, small indel/frameshift, and non-coding (deep intronic, promoter/UTR) variants have all been reported. Critically, no patient has two complete null alleles — this genotype is presumed embryonic lethal, consistent with mouse knockout data (see §15) (PMID:28191891). - A recurrent homozygous missense variant, c.631C>T p.(Arg211Cys), has been independently identified in unrelated families with the Meier-Gorlin phenotype, suggesting either a mutational hotspot or a shared ancestral/founder allele in some populations (PMC6936249; recent Turkish-family case report, PMID:41612845). - A recurrent K489T substitution and a noncoding variant disrupting exon 4/5 splicing have also been described as causing exon skipping and nonsense-mediated decay or post-transcriptional destabilization of DONSON protein (PMID:28191891; PMC5538549 — the noncoding "genome-and-transcriptome sequencing" MIMIS discovery). - Genotype–phenotype correlation: variants affecting exon 4 have been associated with the milder MGS/FFS end of the spectrum, whereas frameshift variants and those in exons 5–10 correlate with more severe microcephaly and developmental impairment (PMC6936249). - Variants are rare in population databases (reported at <0.5% frequency in ExAC in the original description; no specific carrier-frequency or founder-population data were identified in this search beyond the shared p.Arg211Cys recurrence).

Environmental/other risk factors: None established; this is a purely monogenic disorder with no known environmental, infectious, or lifestyle contributory factors.

Protective factors: None reported.

Gene-environment interactions: Not applicable/not reported.

3. Phenotypes

The DONSON phenotypic spectrum shares a common "core" triad — profound microcephaly, growth restriction, and skeletal anomalies — of variable severity:

Onset: Prenatal (severe end — detectable IUGR and microcephaly on antenatal ultrasound) through neonatal presentation for milder forms.

Severity/progression: Static/non-progressive congenital malformation and growth pattern once established (not a degenerative disease), but growth deficiency and microcephaly are lifelong. Severity is graded along the described spectrum from perinatally lethal MIMIS to milder, non-lethal MISSLA/MGS-like presentations with survival into childhood/adulthood.

Quality of life: Limited direct QoL data; morbidity relates to short stature, skeletal deformity, and (in a subset) mild intellectual disability affecting educational/functional outcomes. No specific EQ-5D/SF-36 data identified.

4. Genetic / Molecular Information

• Causal gene: DONSON (HGNC:2993, OMIM *611428), chromosome 21q22.11.
• Variant classes observed: missense, nonsense, frameshift, canonical and non-canonical splice-site variants, and at least one deep intronic/regulatory noncoding variant causing aberrant splicing (identified via combined genome+transcriptome sequencing in a MIMIS family; PMC5538549).
• ACMG classification: Reported variants are generally classified pathogenic/likely pathogenic in ClinVar (e.g., NM_017613.4:c.1466A>C p.(Lys489Thr); c.82A>C p.(Ser28Arg)) in the context of biallelic inheritance.
• Functional consequence: All disease variants are hypomorphic (partial loss of function) rather than complete null — consistent with the embryonic lethality of complete DONSON loss. Mechanisms of hypomorphism include: exon skipping leading to partial nonsense-mediated decay, post-transcriptional protein destabilization (e.g., the K489T variant), subcellular mislocalization, and reduced ability to rescue replication defects in functional assays (e.g., R217C severely impairs function while M463T remains largely functional in complementation assays) (PMID:28191891; academic.oup.com/nar/51/18/9748).
• Inheritance: Autosomal recessive in the great majority of cases; rare compound heterozygous cases include one de novo allele (e.g., the femoral-facial syndrome patient with de novo c.683G>T p.(Trp228Leu)) (PMC6936249).
• Modifier genes: None specifically established.
• Epigenetics: No disease-specific epigenetic (DNA methylation/histone) data identified.
• Chromosomal abnormalities: Not a copy-number/structural disorder — point mutations and small indels/splice variants predominate; not associated with 21q22 microdeletion/duplication syndromes as a class (though 21q22.11 duplications encompassing DONSON have been studied for partial trisomy 21 phenotypes in an unrelated context; PMC5102301).

5. Environmental Information

Not applicable — this is a purely monogenic Mendelian disorder. No toxin, lifestyle, or infectious contributory factors have been identified in the literature reviewed.

6. Mechanism / Pathophysiology

Core molecular function of DONSON. DONSON is a replisome component essential for both (a) origin firing/replication initiation and (b) replication fork stability during elongation:

• Replication initiation: DONSON is required for Cdc45 and GINS chromatin association with the MCM2-7 helicase and is essential for assembly of the active CMG (Cdc45-MCM-GINS) replicative helicase at replication origins (PMID:37638758; academic.oup.com/nar/51/18/9748). Recent structural work shows DONSON acts as a dimerization scaffold that synchronizes the delivery of two GINS complexes to the pre-replication complex, even though GINS itself cannot dimerize (PMC10996697; "structural mechanism of dimeric DONSON in replicative helicase activation," PMC7616792/ScienceDirect S109727652300761X). DONSON interacts with the initiation master-regulator TopBP1 in a CDK-dependent manner, and together with RecQL4 transiently docks the pre-replication complex before origin firing, without itself traveling with the elongating fork.
• Fork stability: During S-phase, DONSON protein levels peak in parallel with Cyclin A and it associates with MCM helicase subunits, the GINS complex, PCNA, Treslin, and RPA to prevent spontaneous replication fork stalling during unperturbed DNA synthesis (PMID:28191891).

Consequence of DONSON hypomorphism: 1. Patient-derived and DONSON-depleted cells show elevated spontaneous replication fork asymmetry and stalling. 2. Stalled forks undergo pathological nucleolytic cleavage by the structure-specific endonucleases MUS81 and XPF, generating severe replication-associated DNA damage. 3. The ATR-dependent intra-S and G2/M checkpoints are impaired — reduced phosphorylation of CHK1 and NBS1 — so cells fail to properly arrest and repair in response to this damage ("Loss of DONSON leads to severe replication-associated DNA damage arising from nucleolytic cleavage of stalled replication forks," PMID:28191891). 4. Separately, DONSON depletion causes premature centriole disengagement during interphase, generating supernumerary centrosomes that drive abnormal mitotic spindle formation and chromosome segregation errors — a distinct centrosome-cycle mechanism proposed to compound the replication-stress phenotype (bioRxiv 2020.05.10.086777; later peer-reviewed).

Cell-type and tissue vulnerability — causal chain to microcephaly: Neural progenitor cells are exquisitely sensitive to replication stress because of their extremely high proliferative demand during cortical neurogenesis. Conditional mouse knockout studies (necessary because germline Donson loss is embryonic lethal) show that: - Cre-mediated Donson deletion in progenitors of both cortical glutamatergic (dorsal telencephalon/neocortex, hippocampus) and GABAergic (subpallial, Nkx2.1+ lineage) neurons causes extensive apoptosis in both the proliferative zones and postmitotic differentiation zones. - Nkx2.1-Cre-mediated deletion ablated ~75% of Nkx2.1-derived cortical GABAergic interneurons, and progenitors generating cortical interneurons and oligodendrocyte precursors were also affected (PLOS Genetics, PMC8011756/PMID via journals.plos.org/plosgenetics/10.1371/journal.pgen.1009441). - This establishes microcephaly in DONSON disease as a progenitor-depletion mechanism: replication-stress-induced apoptosis in rapidly dividing neuroepithelial and interneuron progenitor pools, rather than a primary neuronal degeneration process.

Suggested GO terms: GO:0006260 (DNA replication), GO:0031297 (replication fork processing), GO:0000076 (DNA replication checkpoint signaling), GO:0007099 (centriole replication), GO:0000086 (G2/M transition of mitotic cell cycle). Suggested CL terms: CL:0000047 (neural stem cell) / CL:0002605 (neural progenitor cell), CL:0000617 (GABAergic neuron), CL:0000679 (glutamatergic neuron).

7. Anatomical Structures Affected

• Organ/system level: Central nervous system (brain — cerebral cortex, corpus callosum), skeletal system (limbs — radial ray, patella, digits; craniofacial skeleton — skull sutures, mandible, ears), growth/endocrine axis (generalized somatic growth failure). No primary cardiac, renal, or hepatic involvement is characteristic of the core phenotype (distinguishing it from some other MPDs).
• Tissue/cell level: Neuroepithelial progenitors and cortical interneuron progenitors (proliferation and differentiation zones); chondro-osseous tissue of the growth plate and appendicular skeleton.
• Subcellular level: DNA replication fork/replisome (nuclear, chromatin-associated), centrosome/centriole.
• UBERON suggestions: UBERON:0000955 (brain), UBERON:0000956 (cerebral cortex), UBERON:0002331 (corpus callosum), UBERON:0002102 (forelimb/radius), UBERON:0002337 (patella).
• Laterality: Generally bilateral/symmetric (microcephaly, growth restriction); limb involvement can be asymmetric in some case reports.

8. Temporal Development

• Onset: Prenatal in the severe end of the spectrum (detectable IUGR, microcephaly, and limb anomalies on antenatal ultrasound in MIMIS); congenital/neonatal in milder MISSLA/MGS-like presentations.
• Course: A static congenital malformation/growth syndrome rather than a progressive neurodegenerative disease — microcephaly and short stature are present from birth and persist, without a described post-natal regression phase.
• Severity spectrum (disease "stages" in effect): MIMIS (prenatal/perinatal lethal) → Seckel-like/severe microcephaly with developmental delay → MGS-like (short stature, ear/patella anomalies) → FFS-like → MISSLA (mildest, survivable into childhood with mild ID). Authors have proposed these represent "a continuum of the same clinical spectrum of cell cycle-opathies, rather than discrete clinical entities" (PMC6936249).
• Critical period: Embryonic/fetal neurogenesis and skeletal patterning windows, given the progenitor-depletion mechanism.

9. Inheritance and Population

• Inheritance pattern: Autosomal recessive (biallelic hypomorphic variants); rare de novo/compound heterozygous cases reported.
• Penetrance/expressivity: Full penetrance for biallelic hypomorphic genotypes but markedly variable expressivity (phenotype severity is genotype-dependent, per the exon 4 vs exons 5–10 correlation noted above).
• Prevalence/incidence: Ultra-rare; exact population prevalence is not established. Total published cases across all DONSON-associated phenotypes number in the tens (the founding 2017 series described 29 individuals with biallelic DONSON mutations across multiple families; subsequent series added further families through 2019–2026).
• Consanguinity: A notable proportion of reported families are consanguineous (homozygous variants identified via autozygosity mapping in several reports), consistent with a rare autosomal recessive disorder.
• Founder effects: The recurrent p.(Arg211Cys) allele has now been reported in multiple, apparently unrelated families (including a Turkish family, PMID:41612845), raising the possibility of a mutational hotspot or a shared founder haplotype — not conclusively established from available sources.
• Sex ratio / geographic distribution: No skewed sex ratio reported (consistent with autosomal inheritance); cases have been reported across diverse populations (European, Middle Eastern/Turkish, and others) without a described endemic geographic pattern.

10. Diagnostics

• Primary diagnostic approach: Clinical suspicion based on the combination of severe (disproportionate) microcephaly, IUGR/short stature, and characteristic skeletal (radial ray, patellar) and craniofacial features, confirmed by molecular genetic testing.
• Genetic testing:
• Exome/genome sequencing is the primary diagnostic modality used in essentially all published cases; several diagnoses were made via research-based whole-exome or whole-genome sequencing, including one case solved only by combined genome + transcriptome (RNA) sequencing to detect a noncoding splice-disrupting variant not identifiable by exome alone (PMC5538549).
• Targeted gene panels for microcephalic primordial dwarfism / Meier-Gorlin syndrome / Seckel syndrome typically now include DONSON alongside ORC1, ORC4, ORC6, CDT1, CDC6, GMNN, CDC45, MCM5, PCNT, ATR, RNU4ATAC, etc.
• Single-gene sequencing of DONSON is reasonable when the clinical gestalt is highly suggestive (e.g., recurrent p.Arg211Cys hotspot).
• Chromosomal microarray/karyotype are used to exclude alternative chromosomal causes of microcephalic dwarfism but are not diagnostic for DONSON disease itself.
• Imaging: Prenatal ultrasound (severe IUGR, microcephaly, limb shortening) and postnatal brain MRI (simplified gyral pattern, reduced cortical volume, hypoplastic/absent corpus callosum in severe cases) and skeletal radiographs (patellar aplasia/hypoplasia, radial ray anomalies).
• Differential diagnosis: Other microcephalic primordial dwarfisms — MOPD I (RNU4ATAC), MOPD II (PCNT), Seckel syndrome (ATR, CENPJ, CEP152, etc.), other Meier-Gorlin syndrome genes (ORC1/4/6, CDT1, CDC6, GMNN, CDC45, MCM5), 3-M syndrome, and Cornelia de Lange syndrome, need to be distinguished — genetically definitive but clinically overlapping.
• Screening: No population/newborn screening program exists (ultra-rare Mendelian disorder); prenatal diagnosis via targeted variant testing is possible in families with a known DONSON variant, and preimplantation genetic diagnosis is theoretically applicable for known-carrier couples.

11. Outcome / Prognosis

• Survival: Bimodal by phenotype severity — the MIMIS end of the spectrum is associated with intrauterine fetal death or perinatal lethality (severe growth restriction, microcephaly, and limb malformation incompatible with survival in the most severe reported fetuses). The MISSLA/MGS-like end of the spectrum is compatible with survival into childhood and beyond, albeit with lifelong short stature, microcephaly, and (in some) mild intellectual disability.
• Morbidity: Persistent short stature, microcephaly, and skeletal (particularly upper-limb/radial ray) anomalies; mild intellectual disability and speech delay in a subset of survivors.
• No disease-specific FDA-approved therapy exists — as with the great majority of ultra-rare Mendelian disorders (only ~5% of rare diseases overall have an FDA-approved treatment).
• Prognostic factors: Variant location/type appears to be the major driver of severity (exon 4 missense variants → milder MGS/FFS phenotype; frameshift and exon 5–10 variants → more severe microcephaly/developmental impairment) (PMC6936249).

12. Treatment

No disease-modifying or curative therapy exists for DONSON-related disease; management is entirely supportive and multidisciplinary, analogous to management approaches used across the microcephalic primordial dwarfism spectrum (e.g., MOPD II):

• Growth management: Auxological monitoring; growth hormone therapy is sometimes trialed empirically in primordial dwarfism syndromes generally, though no DONSON-specific efficacy data were identified in this search (suggested NCIT term: NCIT:C15986 Pharmacotherapy, generic, if used).
• Neurodevelopmental support: Early intervention, physical/occupational/speech therapy (NCIT:C15302 Physical Therapy; NCIT:C159273 Speech Therapy; NCIT:C121351 Occupational Therapy) for developmental delay and mild intellectual disability.
• Orthopedic management: Surgical correction of severe radial ray/thumb anomalies or patellar instability where functionally indicated (NCIT:C15329 Surgical Procedure; NCIT:C16186 Orthopedic Surgical Procedure).
• Genetic counseling: Essential for affected families given autosomal recessive inheritance and 25% recurrence risk per pregnancy for carrier couples; prenatal diagnosis/PGD offered where a familial variant is known (NCIT:C15240 Genetic Counseling).
• Multidisciplinary surveillance: As generalized for MPD/MOPD-spectrum disorders, follow-up should monitor for comorbidities described in related MPDs (e.g., MOPD II) such as cerebral vasculopathy, though DONSON-specific vasculopathy risk is not established in the literature reviewed — this should be treated as an extrapolation from the broader MPD category rather than a DONSON-specific finding.
• Experimental/investigational therapy: None identified in ClinicalTrials.gov or the literature reviewed; no gene therapy, small-molecule, or targeted approach is in development specifically for DONSON disease as of this search.

13. Prevention

• Primary prevention: Not applicable (Mendelian genetic disorder) beyond genetic counseling and reproductive options (carrier screening, prenatal diagnosis, PGD) in families with a known pathogenic variant.
• Secondary prevention: Early molecular diagnosis enables anticipatory multidisciplinary surveillance (growth, neurodevelopment, orthopedic) but does not prevent disease onset.
• Public health measures: None applicable — no environmental or infectious component.

14. Other Species / Natural Disease

No naturally occurring DONSON-related disease has been reported in non-human species in the literature surveyed here (no OMIA entries or veterinary case reports identified). DONSON orthologs exist across vertebrates (used experimentally in mouse and presumably zebrafish/other model systems — see below), but no spontaneous animal disease analog was found.

15. Model Organisms

• Mouse (Mus musculus):
• Constitutive/germline Donson knockout is embryonic lethal early in development — directly supporting the inference that all human disease alleles must be hypomorphic, since a complete null is not compatible with life (ResearchGate table, "Donson loss of function is lethal in early embryonic mouse development," referencing PMID:28191891 supplementary data).
• Conditional (Cre-lox) knockout models were therefore developed to study tissue-specific roles. Donson is widely expressed in proliferative and differentiation zones of the embryonic dorsal and ventral telencephalon, with expression declining postnatally.
  • Emx1-Cre-mediated deletion in the dorsal telencephalic (cortical excitatory/glutamatergic) lineage and Nkx2.1-Cre-mediated deletion in the ventral (GABAergic interneuron) lineage both caused extensive apoptosis in proliferating progenitors and postmitotic differentiating cells, with Nkx2.1-Cre deletion ablating ~75% of Nkx2.1-derived cortical GABAergic interneurons and also affecting oligodendrocyte precursor generation (PLOS Genetics 2021, PMC8011756).
• This conditional-knockout model recapitulates the human microcephaly phenotype at the cellular/progenitor level (progenitor loss via apoptosis) though it does not model the skeletal/limb component of the human disease.
• Patient-derived cell lines: Primary fibroblasts and lymphoblastoid lines from affected individuals are the principal human cellular model, showing increased spontaneous replication fork stalling/asymmetry, impaired ATR checkpoint signaling (reduced CHK1/NBS1 phosphorylation), and elevated S-phase DNA damage — used extensively for functional variant characterization (complementation/rescue assays) (PMID:28191891; academic.oup.com/nar/51/18/9748).
• In vitro/biochemical systems: Cell-free Xenopus egg extract and reconstituted human replication systems have been used to define DONSON's biochemical role in CMG helicase assembly and its dimeric GINS-scaffolding function (single-molecule imaging studies, PMC10996697; PMC7616792).
• Invertebrate models (Drosophila, zebrafish, C. elegans): No DONSON-specific knockout/mutant phenotype data were identified in this search; general zebrafish microcephaly-modeling methodology exists for other MCPH genes but no DONSON-specific zebrafish study was found.
• Model limitations: The mouse conditional-knockout system captures the neural progenitor-depletion/microcephaly mechanism well but does not reproduce the skeletal (limb, patellar) phenotype seen in humans, and — because human disease alleles are hypomorphic rather than null — a true knockout may over-represent the severity of pathway disruption relative to the partial-function state present in patients.

Sources

• Mutations in DONSON disrupt replication fork stability and cause microcephalic dwarfism — Reynolds JJ et al., Nat Genet 2017;49(4):537–549, PMID:28191891 (PMC5450907)
• Biallelic and De Novo Variants in DONSON Reveal a Clinical Spectrum of Cell Cycle-opathies with Microcephaly, Dwarfism and Skeletal Abnormalities — Kim/Karaca et al., Am J Med Genet A 2019, PMID:31407851 (PMC6936249)
• Integrated genome and transcriptome sequencing identifies a noncoding mutation in the genome replication factor DONSON as the cause of microcephaly-micromelia syndrome (PMC5538549)
• Further Delineation of the Microcephaly-Micromelia Syndrome Associated with Loss-of-Function Variants in DONSON — Molecular Syndromology (PMC6528082)
• Microcephalic primordial dwarfism with predominant Meier-Gorlin phenotype, ichthyosis, and multiple joint deformities — PMID:35298084
• Meier-Gorlin syndrome due to a recurrent DONSON variant in a Turkish family — PMID:41612845
• Linked-read genome sequencing identifies biallelic pathogenic variants in DONSON as a novel cause of Meier-Gorlin syndrome (PMC7042968)
• Microcephaly, short stature, and limb abnormality disorder due to novel autosomal biallelic DONSON mutations in two German siblings — Eur J Hum Genet (PMC6117362)
• DONSON facilitates Cdc45 and GINS chromatin association and is essential for DNA replication initiation — Nucleic Acids Research 2023, PMID:37638758
• Single-Molecule Imaging Reveals the Mechanism of Bidirectional Replication Initiation in Metazoa (PMC10996697)
• The structural mechanism of dimeric DONSON in replicative helicase activation
• DONSON, a gene responsible for microcephalic primordial dwarfism, ensures proper centriole duplication cycle by maintaining centriole engagement during interphase — bioRxiv
• The microcephaly gene Donson is essential for progenitors of cortical glutamatergic and GABAergic neurons — PLOS Genetics 2021 (PMC8011756)
• OMIM #617604 — Microcephaly, Short Stature, and Limb Abnormalities (MISSLA)
• OMIM *611428 — DOWNSTREAM NEIGHBOR OF SON; DONSON
• OMIM #251230 — Microcephaly-Micromelia Syndrome
• Orphanet: DONSON — DNA replication fork stabilization factor DONSON
• Orphanet: Microcephaly-micromelia syndrome (ORPHA:572768)
• GARD/NIH: DONSON-related microcephaly-short stature-limb abnormalities spectrum
• The expanding genetic and clinical landscape associated with Meier-Gorlin syndrome — Eur J Hum Genet 2023
• DONSON Gene — GeneCards
• Primordial Dwarfism Information Sheet — University of Chicago Genetic Services Laboratory

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMC:PMC6936249 (abstract only): "a continuum of the same clinical spectrum of cell cycle-opathies, rather than discrete clinical entities"
• closest text in source: "Genes associated with these syndromes encode proteins that have crucial roles in DNA replication or in other critical steps of the cell cycle that link DNA replication to cell division"